BioSpace News Archive

Pharm Country

Global Foundation for Human Aging Research Contributes $75,000 to Support the Dana-Farber Cancer Institute in its Cellular Aging Research

The Global Foundation for Human Aging Research announces a donation of $75,000 to Dana-Farber Cancer Institute, the cancer treatment and research center designated by the National Cancer Institute in Boston, MA, and affiliate of Harvard Medical School.

December 29, 2017

·

2 min read

Pharm Country

Delcath Announces Exit From Convertible Note

The number of shares of the Company’s issued and outstanding common stock immediately following issuance of the initial Shares to the investors is 114,054,852.

December 29, 2017

·

5 min read

Policy

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma

The FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).

December 29, 2017

·

5 min read

Policy

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome

In October 2017, GW completed the submission of its rolling Epidiolex NDA to the FDA, also for seizures associated with LGS and Dravet syndrome.

December 29, 2017

·

6 min read

Mylan Adds to U.S. Women’s Healthcare Portfolio With FDA Approval of First Generic for Estrace Cream

Mylan N.V. today announced the U.S. launch of Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan’s Estrace Cream.

December 29, 2017

·

5 min read

Drug Development

Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility

This will be the site where the Company’s research arm, Cannevert Therapeutics will be conducting its first human study of CTL-X, a cannabis strain targeting pain management.

December 29, 2017

·

4 min read

Business

CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments

CEL-SCI reported a net loss of ($14.36) million in fiscal year 2017 versus a net loss of ($11.51) million in fiscal 2016.

December 29, 2017

·

5 min read

Drug Development

Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor

The company intends to initiate the TITAN study, a first-in-human study of RXDX-106 in patients with locally advanced or metastatic solid tumors.